MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Annals of Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,693 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,693 works in the cohort · of 4,299,418page 18 of 54

Labels cover 15 of 2,693 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,693 of 2,693 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

aboutno affunlabeled
Funding sources of practice-changing trials
Semih Doğan, Mutsuko Yamamoto‐Ibusuki, Fabrice André
2017· letter· en· Annals of Oncology· Pharmacology, Toxicology and Pharmaceutics
machine prediction:candidate · metaresearchconsensus · metaresearch
13
citations
affno abstractunlabeled
LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE
K.N. Chi, Elena Castro, Gerhardt Attard, Matthew R. Smith, Shahneen Sandhu, Eleni Efstathiou +14 more
2023· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
12
citations
affno abstractunlabeled
Diabetes, metformin and breast cancer: a tangled web
Ana Elisa Lohmann, Pamela J. Goodwin
2021· letter· en· Annals of Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
11
citations
affno abstractunlabeled
LBA81 Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: A randomised, phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma
J. Tabernero, S-E. Al-Batran, Zev A. Wainberg, K. Muro, D. Molena, E. Van Cutsem +14 more
2025· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
10
citations

How this was built: Screen · Findings · About